Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Jemal, 2009, Cancer statistics, 2009, CA Cancer J Clin, 59, 225, 10.3322/caac.20006

Eisenberger, 1985, A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma, J Clin Oncol, 3, 827, 10.1200/JCO.1985.3.6.827

Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720

Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318

Berry, 2006, Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone, J Clin Oncol, 24, 2828, 10.1200/JCO.2005.04.8207

Rosenberg, 2007, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone, Cancer, 110, 556, 10.1002/cncr.22811

Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, 1756, 10.1200/JCO.1996.14.6.1756

Attard, 2006, Update on tubulin binding agents, Pathol Biol (Paris), 54, 72, 10.1016/j.patbio.2005.03.003

Aller, 2000, In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines, Proc Am Assoc Cancer Res, 41, 303

Bissery, 2000, Preclinical evaluation of TXD258, a new taxoid, Proc Am Assoc Cancer Res, 41, 214

Mita, 2009, Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors, Clin Cancer Res, 15, 723, 10.1158/1078-0432.CCR-08-0596

Pivot, 2008, A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients, Ann Oncol, 19, 1547, 10.1093/annonc/mdn171

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Melzack, 1975, The McGill Pain Questionnaire: major properties and scoring methods, Pain, 1, 277, 10.1016/0304-3959(75)90044-5

Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

de Bono, 2008, Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer, Clin Cancer Res, 14, 6302, 10.1158/1078-0432.CCR-08-0872

Kramer, 2006, Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles, Br J Cancer, 94, 1592, 10.1038/sj.bjc.6603129